Adverum Ebit from 2010 to 2024

ADVM Stock  USD 5.74  0.15  2.55%   
Adverum Biotechnologies EBIT yearly trend continues to be very stable with very little volatility. EBIT is likely to grow to about -112.3 M this year. During the period from 2010 to 2024, Adverum Biotechnologies EBIT quarterly data regression pattern had sample variance of 3194.4 T and median of (58,847,000). View All Fundamentals
 
EBIT  
First Reported
2012-12-31
Previous Quarter
-18.5 M
Current Value
-27.1 M
Quarterly Volatility
15.2 M
 
Yuan Drop
 
Covid
Check Adverum Biotechnologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Adverum Biotechnologies' main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.9 M, Interest Expense of 3.2 M or Selling General Administrative of 31.8 M, as well as many indicators such as Price To Sales Ratio of 23.04, Dividend Yield of 0.0 or PTB Ratio of 0.96. Adverum financial statements analysis is a perfect complement when working with Adverum Biotechnologies Valuation or Volatility modules.
  
Check out the analysis of Adverum Biotechnologies Correlation against competitors.
To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.

Latest Adverum Biotechnologies' Ebit Growth Pattern

Below is the plot of the Ebit of Adverum Biotechnologies over the last few years. It is Adverum Biotechnologies' EBIT historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Adverum Biotechnologies' overall financial position and show how it may be relating to other accounts over time.
Ebit10 Years Trend
Slightly volatile
   Ebit   
       Timeline  

Adverum Ebit Regression Statistics

Arithmetic Mean(60,987,190)
Geometric Mean25,097,902
Coefficient Of Variation(92.67)
Mean Deviation47,557,936
Median(58,847,000)
Standard Deviation56,519,365
Sample Variance3194.4T
Range159M
R-Value(0.90)
Mean Square Error623.5T
R-Squared0.82
Slope(11,435,553)
Total Sum of Squares44722.1T

Adverum Ebit History

2024-112.3 M
2023-118.2 M
2022-154.5 M
2021-145.5 M
2020-116.4 M
2019-68.5 M
2018-68.1 M

Other Fundumenentals of Adverum Biotechnologies

About Adverum Biotechnologies Financial Statements

Adverum Biotechnologies investors utilize fundamental indicators, such as Ebit, to predict how Adverum Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
EBIT-118.2 M-112.3 M
EBITDA-112.6 M-107 M
Ebt Per Ebit 0.96  1.13 
Ebit Per Revenue(39.54)(41.52)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Adverum Biotechnologies is a strong investment it is important to analyze Adverum Biotechnologies' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adverum Biotechnologies' future performance. For an informed investment choice regarding Adverum Stock, refer to the following important reports:
Check out the analysis of Adverum Biotechnologies Correlation against competitors.
To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.95)
Revenue Per Share
0.059
Quarterly Revenue Growth
(0.70)
Return On Assets
(0.30)
Return On Equity
(0.76)
The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adverum Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adverum Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.